AACR 2024 preview – clinical highlights and lowlights
The 2024 AACR abstract title drop features several noteworthy clinical studies.
Deal analysis part three – the undecided
Of the big oncology deals since 2016, there are still plenty that could go either way.
Pfizer takes multiple shots on goal
The company’s post-Seagen ADC portfolio features overlapping targets with differing payloads.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
The new normal in US oncology approvals
Nearly two thirds of key oncology filings are expedited; and what about the ones that aren’t?
Deal analysis part two – the good
A look at big oncology deals since 2016 finds outright success stories hard to come by.
